[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640673":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":93,"collaborators":7,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":7,"enrollmentInfo":105,"targetDuration":7,"studyType":108,"phases":7,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":59,"whyStopped":7,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","TDxd","Observing Trastuzumab Deruxtecan in Patients with HR positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated with Endocrine Therapy",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Study Information Center","CONTACT","+18772409479","information.center@astrazeneca.com",[20,32,41,51,58,66,70,79,86],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Research Site","NOT_YET_RECRUITING","Muscat","Oman","OM",{"type":27,"coordinates":28},"Point",[29,30],58.40778,23.58413,{"lat":30,"lon":29},{"facility":21,"status":22,"city":33,"state":7,"zip":7,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":40,"contacts":7},"Doha","Qatar","QA",{"type":27,"coordinates":37},[38,39],51.53096,25.28545,{"lat":39,"lon":38},{"facility":21,"status":22,"city":42,"state":43,"zip":7,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":50,"contacts":7},"Mecca","Mecca Region","Saudi Arabia","SA",{"type":27,"coordinates":47},[48,49],39.82563,21.42664,{"lat":49,"lon":48},{"facility":21,"status":22,"city":52,"state":7,"zip":7,"country":44,"countryCode":45,"cosmosGeoPoint":53,"geoPoint":57,"contacts":7},"Jeddah",{"type":27,"coordinates":54},[55,56],39.18624,21.49012,{"lat":56,"lon":55},{"facility":21,"status":59,"city":60,"state":7,"zip":7,"country":44,"countryCode":45,"cosmosGeoPoint":61,"geoPoint":65,"contacts":7},"RECRUITING","Riyadh",{"type":27,"coordinates":62},[63,64],46.72185,24.68773,{"lat":64,"lon":63},{"facility":21,"status":22,"city":60,"state":7,"zip":7,"country":44,"countryCode":45,"cosmosGeoPoint":67,"geoPoint":69,"contacts":7},{"type":27,"coordinates":68},[63,64],{"lat":64,"lon":63},{"facility":21,"status":22,"city":71,"state":7,"zip":7,"country":72,"countryCode":73,"cosmosGeoPoint":74,"geoPoint":78,"contacts":7},"Abu Dhabi","United Arab Emirates","AE",{"type":27,"coordinates":75},[76,77],54.39696,24.45118,{"lat":77,"lon":76},{"facility":21,"status":22,"city":80,"state":7,"zip":7,"country":72,"countryCode":73,"cosmosGeoPoint":81,"geoPoint":85,"contacts":7},"Al Ain City",{"type":27,"coordinates":82},[83,84],55.76056,24.19167,{"lat":84,"lon":83},{"facility":21,"status":22,"city":87,"state":7,"zip":7,"country":72,"countryCode":73,"cosmosGeoPoint":88,"geoPoint":92,"contacts":7},"Dubai",{"type":27,"coordinates":89},[90,91],55.30927,25.07725,{"lat":91,"lon":90},{"type":94,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100640673","beyond-study-a-multicentre-prospective-observational-study-of-real-world-treatment-patterns-and-outcomes-of-trastuzumab-deruxtecan-in-patients-with-hr-positive-her2-low-or-ultra-low-metastatic-breast-cancer-previously-treated-with-endocrine-therapy-100640673",false,"NCT07597993","BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","BEYOND","Inclusion Criteria:\n\n* -Female patients aged ≥18 years old at the time of T-DXd initiation\n* Patients with a confirmed histological or cytologically based diagnosis of HR-positive mBC.\n* Patients who were classified as HER2-low or HER2-ultralow mBC confirmed by the closest locally obtained HER2 test prior to or on the index date, and who meet the following definitions:\n* HER2-low status defined as IHC scores 1+ and 2+ without ISH gene amplification based on the pathology report.\n* HER2-ultralow status defined as IHC 0 with membrane staining based on the pathology report.\n* Patient who received at least one prior line of ET (± targeted therapy) in the metastatic setting.\n* Patients who are chemotherapy-naïve in the metastatic setting.\n* Patients who initiated T-DXd up to 30 days before the signature of the ICF. The decision to initiate T-DXd must be made independently by treating physicians as part of routine clinical practice.\n* Patients are willing to sign the written ICF, indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n* -Patients with a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.\n* Patients who received prior chemotherapy in the metastatic setting.\n* Patients with Eastern Cooperative Oncology Group (ECOG) status ≥2 or missing ECOG status at the time of initiation of T-DXd (index date).\n* Patients with a history of participation in another clinical trial in the metastatic setting.\n* Female patient with current or planned pregnancy, or breastfeeding.","FEMALE","18 Years",{"count":106,"type":107},109,"ESTIMATED","OBSERVATIONAL","BEYOND study is designed to generate the first real-world data from GCC countries on the patient characteristics, treatment patterns, survival outcomes, and safety of T-DXd in patients with HRpositive,HER2-low or HER2-ultralow mBC previously treated with ET. The evidence generated will help to optimise treatment strategies, inform clinical guidelines, and ultimately improve outcomes for patients with mBC across the region.",[111],"Breast Cancer",[113,114],"breast cancer","Trastuzumab Deruxtecan","2026-08-06",{"date":117,"type":118},"2026-08-10","ACTUAL",{"date":120,"type":118},"2026-07-12",{"date":122,"type":107},"2029-03-31",{"name":5,"class":6},9]